Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669389 | 0.79 | LMNA (0.34) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL9235255 | 0.79 | LMNA (0.44) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL18259766 | 0.78 | TGFBR1 (0.39) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL10770007 | 0.78 | PDE4A (0.50) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL812714 | 0.78 | PDE4A (0.50) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL468790 | 0.78 | PDE4A (0.50) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL468705 | 0.78 | PDE4A (0.50) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL468798 | 0.78 | PDE4A (0.50) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL27182003 | 0.78 | PDE4A (0.50) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL11225324 | 0.78 | PDE4A (0.50) | LMNAL3MBTL1KDM4EPDE4ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977285-B2 | Oligomers containing N-acetyl glucosamine (NAG) | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-12-20 | — | — | US | claimed |
| EP-1699833-B1 | OLIGOMERS CONTAINING N-ACETYL GLUCOSAMINE | COUNCIL SCIENT IND RES (IN) | 2008-09-24 | — | — | EP | disclosed |
| EP-1699833-A1 | OLIGOMERS CONTAINING N-ACETYL GLUCOSAMINE | Council of Scientific and Industrial Research (IN) | 2006-09-13 | — | — | EP | disclosed |
| EP-1615940-A1 | POLYMERIZABLE MONOMERS AND PROCESS OF PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2006-01-18 | — | — | EP | disclosed |
| US-6977285-B2 | Oligomers containing N-acetyl glucosamine (NAG) | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-12-20 | — | — | US | disclosed |
| US-20050222326-A1 | OLIGOMERS CONTAINING N-ACETYL GLUCOSAMINE (NAG) | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2005-10-06 | — | — | US | disclosed |
| WO-2005063833-A1 | OLIGOMERS CONTAINING N-ACETYL GLUCOSAMINE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-07-14 | — | — | WO | disclosed |
| WO-2004087725-A1 | POLYMERIZABLE MONOMERS AND PROCESS OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-14 | — | — | WO | disclosed |
| US-20040192905-A1 | Polymerizable monomers and process of preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL (IN) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192905-A1 | Polymerizable monomers and process of preparation thereof | FUT6, B3GNT2, ALG1 | LMNA 409/4885L3MBTL1 382/4885KDM4E 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.